Cargando…
Evaluation of the Optimal Position for Vedolizumab in the Japanese Treatment Paradigm for Ulcerative Colitis Using Markov Modeling
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802470/ https://www.ncbi.nlm.nih.gov/pubmed/36780243 http://dx.doi.org/10.1093/crocol/otaa036 |
| _version_ | 1784861687843651584 |
|---|---|
| author | Uda, Akihito Eto, Yuki Li, Yuxin Matsuda, Hiroyuki Demiya, Sven Watanabe, Tomoyuki Ota, Mihoko Iwakiri, Ryuichi Igarashi, Ataru |
| author_facet | Uda, Akihito Eto, Yuki Li, Yuxin Matsuda, Hiroyuki Demiya, Sven Watanabe, Tomoyuki Ota, Mihoko Iwakiri, Ryuichi Igarashi, Ataru |
| author_sort | Uda, Akihito |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9802470 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Oxford University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-98024702023-02-10 Evaluation of the Optimal Position for Vedolizumab in the Japanese Treatment Paradigm for Ulcerative Colitis Using Markov Modeling Uda, Akihito Eto, Yuki Li, Yuxin Matsuda, Hiroyuki Demiya, Sven Watanabe, Tomoyuki Ota, Mihoko Iwakiri, Ryuichi Igarashi, Ataru Crohns Colitis 360 Corrigendum Oxford University Press 2020-05-30 /pmc/articles/PMC9802470/ /pubmed/36780243 http://dx.doi.org/10.1093/crocol/otaa036 Text en © 2020 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Corrigendum Uda, Akihito Eto, Yuki Li, Yuxin Matsuda, Hiroyuki Demiya, Sven Watanabe, Tomoyuki Ota, Mihoko Iwakiri, Ryuichi Igarashi, Ataru Evaluation of the Optimal Position for Vedolizumab in the Japanese Treatment Paradigm for Ulcerative Colitis Using Markov Modeling |
| title | Evaluation of the Optimal Position for Vedolizumab in the Japanese Treatment Paradigm for Ulcerative Colitis Using Markov Modeling |
| title_full | Evaluation of the Optimal Position for Vedolizumab in the Japanese Treatment Paradigm for Ulcerative Colitis Using Markov Modeling |
| title_fullStr | Evaluation of the Optimal Position for Vedolizumab in the Japanese Treatment Paradigm for Ulcerative Colitis Using Markov Modeling |
| title_full_unstemmed | Evaluation of the Optimal Position for Vedolizumab in the Japanese Treatment Paradigm for Ulcerative Colitis Using Markov Modeling |
| title_short | Evaluation of the Optimal Position for Vedolizumab in the Japanese Treatment Paradigm for Ulcerative Colitis Using Markov Modeling |
| title_sort | evaluation of the optimal position for vedolizumab in the japanese treatment paradigm for ulcerative colitis using markov modeling |
| topic | Corrigendum |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802470/ https://www.ncbi.nlm.nih.gov/pubmed/36780243 http://dx.doi.org/10.1093/crocol/otaa036 |
| work_keys_str_mv | AT udaakihito evaluationoftheoptimalpositionforvedolizumabinthejapanesetreatmentparadigmforulcerativecolitisusingmarkovmodeling AT etoyuki evaluationoftheoptimalpositionforvedolizumabinthejapanesetreatmentparadigmforulcerativecolitisusingmarkovmodeling AT liyuxin evaluationoftheoptimalpositionforvedolizumabinthejapanesetreatmentparadigmforulcerativecolitisusingmarkovmodeling AT matsudahiroyuki evaluationoftheoptimalpositionforvedolizumabinthejapanesetreatmentparadigmforulcerativecolitisusingmarkovmodeling AT demiyasven evaluationoftheoptimalpositionforvedolizumabinthejapanesetreatmentparadigmforulcerativecolitisusingmarkovmodeling AT watanabetomoyuki evaluationoftheoptimalpositionforvedolizumabinthejapanesetreatmentparadigmforulcerativecolitisusingmarkovmodeling AT otamihoko evaluationoftheoptimalpositionforvedolizumabinthejapanesetreatmentparadigmforulcerativecolitisusingmarkovmodeling AT iwakiriryuichi evaluationoftheoptimalpositionforvedolizumabinthejapanesetreatmentparadigmforulcerativecolitisusingmarkovmodeling AT igarashiataru evaluationoftheoptimalpositionforvedolizumabinthejapanesetreatmentparadigmforulcerativecolitisusingmarkovmodeling |